FindTrial
Sign In

Treatment outcome and safety of afatinib in advanced Squamous cell lung cancer Progressed After platinum-based doublet Chemotherapy with immunotherapy

SPACE study: Treatment outcome and safety of afatinib in advanced Squamous cell lung cancer Progressed After platinum-based doublet Chemotherapy with immunotherapy: a real world evidence from chart review rEgistry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0005712
Enrollment
52
Registered
2020-12-29
Start date
2021-04-16
Completion date
Unknown
Last updated
2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Kyung Hee University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Retrospective cohort: patients who have completed afatinib treatment between September 2018 and the day before the starting day of this study. Prospective cohort: patients who are treated with afatinib without disease progression at study initiation, or patients who are to initiate afatinib after study initiation. 1) Patients who recieved afatinib in locally advanced, metastatic or recurrent squamous cell carcinoma of lung progressed after platinum-based chemotherpay with/without immunotherapy from September 2018 to November 2021. 2) Patients who provide written informed consent for the study (But, obtaining informed consent will be exempted for patients in a retrospective cohort or expired patients)

Exclusion criteria

Exclusion criteria: 1) Patients who were treated with other EGFR-TKIs 2) Illiterate 3) Women of pregnant or childbearing potential who are planning on becoming pregnant 4) patinets under the age of 19

Design outcomes

Primary

MeasureTime frame
Time to treatment failure (TTF)—

Secondary

MeasureTime frame
Objective response rate (ORR);Progression-free survival (PFS);Overall survival (OS);Disease control rate (DCR);Duration of Response (DR);Differences in TTF, PFS, and OS according to genetic alterations and PD-L1 expression status;Safety profile—

Countries

Korea, Republic of

Contacts

Public ContactSeung Hyeun Lee

Kyung Hee University Hospital

humanmd04@hanmail.net+82-2-958-8511

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026